Crinone is a drug owned by Abbvie Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 15, 2013. Details of Crinone's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5543150 | Method of progesterone delivery and affect thereof |
Sep, 2013
(13 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but
Crinone is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Crinone's family patents as well as insights into
ongoing legal events
on those patents.
Crinone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Crinone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Crinone's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 15, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Crinone Generic API suppliers:
Progesterone is the generic name for the brand Crinone. 12 different companies have already filed for the generic of Crinone, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Crinone's generic
Alternative Brands for Crinone
Crinone which is used for hormonal support in women, such as in hormone replacement therapy or fertility treatments., has several other brand drugs using the same active ingredient (Progesterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Covis |
| ||
| Ferring |
| ||
| Ferring Pharms Inc |
| ||
| Mayne Pharma |
| ||
| Pfizer |
| ||
| Wyeth Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Progesterone, Crinone's active ingredient. Check the complete list of approved generic manufacturers for Crinone
About Crinone
Crinone is a drug owned by Abbvie Inc. It is used for hormonal support in women, such as in hormone replacement therapy or fertility treatments. Crinone uses Progesterone as an active ingredient. Crinone was launched by Abbvie in 1997.
Approval Date:
Crinone was approved by FDA for market use on 31 July, 1997.
Active Ingredient:
Crinone uses Progesterone as the active ingredient. Check out other Drugs and Companies using Progesterone ingredient
Treatment:
Crinone is used for hormonal support in women, such as in hormone replacement therapy or fertility treatments.
Dosage:
Crinone is available in gel form for vaginal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 8% | GEL | Prescription | VAGINAL |
| 4% | GEL | Discontinued | VAGINAL |